Skip to main content

Peer Review reports

From: Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn’s disease

Original Submission
17 May 2023 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
7 Jul 2023 Reviewed Reviewer Report
13 Nov 2023 Reviewed Reviewer Report - Nikolas Dussias
13 Nov 2023 Reviewed Reviewer Report
5 Dec 2023 Author responded Author comments - Bruce E. Sands
Resubmission - Version 3
5 Dec 2023 Submitted Manuscript version 3
Publishing
6 Dec 2023 Editorially accepted
20 Dec 2023 Article published 10.1186/s12876-023-03078-7

You can find further information about peer review here.

Back to article page